Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
J3 Bioscience, Inc. Announces Commercial Launch of Groundbreaking LivRing®
J3 Bioscience, Inc., a startup women’s health medical device company, today announced the commercial launch of a first-of-its-kind medical device, LivRing®. This innovative device has the potential to conveniently ease painful sex due to vaginal dryness and improve the lives of countless... - September 18, 2024 - J3 Bioscience, Inc.
US Biologic, Inc. and the Agricultural Research Service Announce Breakthrough Oral Alternative to Antibiotics for Poultry
US Biologic, Inc. and the U.S. Department of Agriculture’s Agricultural Research Service (ARS) announce today findings of a new alternative to antibiotics in the face of coccidiosis and antimicrobial resistance, which cost the poultry industry $3.5B in annual losses worldwide and endanger the... - September 17, 2024 - US Biologic, Inc.
Cromos Pharma Announces the Opening of a New Office in Portugal
Cromos Pharma has opened a new office in Lisbon, Portugal, expanding its presence in Southern Europe. Portugal’s robust healthcare system, EU regulatory alignment, and diverse patient population make it an ideal site for clinical trials. This expansion bolsters Cromos Pharma’s European operations and underscores its commitment to patient-centered research, offering its "No Patients – No Payment" model to minimize sponsor risk. - September 17, 2024 - Cromos Pharma
Valis Corporation Technology Used in Large Brain Model Project
Using Quantum-Entangled Brain Organoids for Artificial Natural and General Intelligence - September 16, 2024 - Valis Corp
Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders
Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.
Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group
ICH1132 Shows Promise in Early-Stage Tumor Growth Inhibition Studies
New comparative study of ichorbio's anti-PD-1 antibody clone RMP1-14 highlights potential for optimized cancer research protocols. - August 21, 2024 - ichorbio Ltd
Huntington Study Group Announces New CEO
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group
Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical
New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.
Creative Biolabs Spearheads Innovative Live Biotherapeutics Against Gut Diseases
Creative Biolabs introduces innovative solutions for live biotherapeutics to empower scientists and pharmaceutical companies in their quest for groundbreaking therapies against gut diseases. - August 03, 2024 - Creative Biolabs
New Study Explores Potential Benefits of Biophoton Generators in Alzheimer's Care
Study results shared at Alzheimer's Association International Conference in Philadelphia. - July 30, 2024 - Tesla BioHealing, Inc.
Thrombolex and Aidoc Announce Strategic Partnership to Advance Breakthrough Pulmonary Embolism Treatment
Thrombolex, Inc., an innovator in the development of advanced interventional medical devices for the treatment of thromboembolic disease, and Aidoc, a pioneering force in clinical AI, are pleased to announce a strategic partnership aimed at revolutionizing the treatment of acute pulmonary embolism... - July 30, 2024 - Thrombolex, Inc.
Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment
Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years
U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process
U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. - July 16, 2024 - microNeb, Inc.
MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy
Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side effects such as nausea and GI discomfort while driving increased weight loss. - July 16, 2024 - Courage Therapeutics
SYNAPS Dx Welcomes Renowned Alzheimer’s Researcher, Dr. Donna Wilcock, to Its Scientific Advisory Board
SYNAPS Dx welcomes Dr. Donna M. Wilcock, a leading Alzheimer's researcher, to its Scientific Advisory Board. Dr. Wilcock's expertise in neuroinflammation and vascular cognitive impairment will support the advancement of the DISCERN™ diagnostic test for Alzheimer's disease. This addition reinforces SYNAPS Dx’s commitment to pioneering accurate, minimally invasive diagnostics for Alzheimer's. For more info, visit SYNAPS Dx's website. - July 15, 2024 - SynapsDx
Huntington Study Group Announces Launch of LEAD-HD Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress... - July 12, 2024 - NuvOx Therapeutics
Morningbird Space Corporation Announces Release of Its Revolutionary 3D Printer Backed by NASA
The Electronic Alchemy eforge series 3.1 is a revolutionary 3D printer capable of creating fully functional electronic devices. The printer was supported by NASA SBIR/STTR and is ready for pre-order. Sensors, circuits, elements, wearable tech, biotechnology, rapid prototyping, and much more is capable with the proprietary filaments from this groundbreaking FDM machine. - July 11, 2024 - Morningbird Space Corporation
SYNAPS Dx Announces Expansion to New, State-of-the-Art Facility
SYNAPS Dx has moved to a new, state-of-the-art facility in Rockville, MD, to meet growing demand and enhance patient care. The larger space and advanced infrastructure will support more diagnostic samples and ensure timely, accurate Alzheimer's and dementia diagnoses. Fully qualified for high-complexity clinical lab testing, the facility boosts diagnostic capabilities. The expansion will also advance the DISCERN™ test, a minimally invasive tool distinguishing Alzheimer's from other dementias. - June 26, 2024 - SynapsDx
Cambridge Polymer Group Unveils Restructure to Accelerate Client Innovation through Material Science
Cambridge Polymer Group (CPG) announced a new leadership structure to better support clients in developing innovative products. CPG is creating a new five-person senior management team with deep materials science expertise, which will allow for closer collaboration with clients on complex projects. Dr. Gavin Braithwaite will be the new CEO and Dr. Stephen Spiegelberg will move to the new role of Chief Scientific Officer (CSO). - June 23, 2024 - Cambridge Polymer Group
M4 Engineering Inc. Acquires Phoenix Technology Works a New Prototyping Powerhouse is Created
M4 Engineering Inc., a leading Engineering, Test, and Prototyping firm in the field of conceptual design, analysis and product development has acquired Phoenix Technology Works (PTW) Maricopa, AZ to increase its footprint in full vehicle prototyping and tooling for composite applications. The... - June 14, 2024 - M4 Engineering
Sosemo LLC Awarded on the Financial Times Americas’ Fastest Growing Companies 2024 List
Sosemo LLC Awarded on the Financial Times Americas’ Fastest Growing Companies 2024 List Sosemo LLC has been awarded on the Financial Times list of The Americas’ Fastest Growing Companies 2024. This prestigious award is presented by the Financial Times and Statista Inc., the... - May 30, 2024 - Sosemo
International Perinatal Stem Cell Society, Inc. and TRI-PAC Health and Wellness Advocacy Have Formed a Strategic Alliance to Advance Stem Cell Legislation
The International Perinatal Stem Cell Society, Inc. and TRI-PAC Health and Wellness Advocacy have formed a strategic alliance to advocate for legal access to safe, effective, and affordable stem cell therapies in the United States. They propose adopting the Japanese model for stem cell therapy regulation, allowing patients to participate in paid clinical trials. The partnership aims to draft and propose a federal bill to improve patient access to stem cell and tissue therapies. - May 24, 2024 - International Perinatal Stem Cell Society, Inc.
RoddyMedical Selected for Mayo Clinic & ASU MedTech Accelerator Program
Company Meets with Top Experts and Brings Home Audience Choice Award - May 23, 2024 - RoddyMedical Inc.
Creative Biolabs Opens Applications for the 2024 Scholarship Program
Creative Biolabs, a leading CRO, is proud to announce the opening of applications for its 2024 scholarship program. This initiative aims to provide financial assistance to students within the biotechnology industry, supporting their academic pursuits and research endeavors. - May 19, 2024 - Creative Biolabs
Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease
AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. - April 30, 2024 - Anzu
Creative Biolabs: Summarizing Malaria Infection Mechanisms and Introducing Biotherapeutic Discovery
Creative Biolabs introduced the discovery of biomolecular approaches targeting Plasmodium, aiming to assist academia and the pharmaceutical industry in relieving the malaria health crisis. - April 25, 2024 - Creative Biolabs
Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development
Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.
Ensuring Reliability for Healthcare Tech at Bio-IT World 2024 with NIX
NIX, a custom software developing company specializing in healthcare solutions, will be at Bio-IT World 2024. They prioritize reliability in their tech, offering secure, scalable, and compliant systems. With 30 years of experience and successful projects for industry leaders, NIX is a trusted partner for healthcare organizations seeking dependable technology solutions. - April 13, 2024 - NIX United
Saelig Introduces Sciospec ISX-3 Electrical Impedance Tomography System
The ISX-3 EIT system allows for simultaneous acquisition of impedance or potential signals on up to 256 electrodes over a broad frequency range of up to 1 MHz. - April 12, 2024 - Saelig Co. Inc.
Huntington Study Group Launches Project AWARE 2.0 Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group
FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity
FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics
Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare
New open-source medchat-qa-descriptive dataset enables AI models to provide comprehensive answers to complex medical queries. - March 22, 2024 - ngram Inc.
Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology
The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.
Bench International Adds Industry Veteran Dr. Renee P. Tannenbaum to Executive Leadership Team
Tannebaum Brings Deep Industry Experience in Pharma and Biotech and Board Expertise to Meet Evolving Life Sciences Talent Demands - March 19, 2024 - Bench International
MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq
MENADNA Inc., has entered into an exclusive partnership with ProPhase Labs' subsidiary, Nebula Genomics, aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities to improve the quality and relevance of genomic data in these historically underserved regions. - March 18, 2024 - MENADNA
Sabina Ewing Awarded Bench and Deloitte Inaugural Life Sciences Tech Innovation Award
Award Recognizes Exceptional Contributions by Women in the Life Sciences Industry - March 15, 2024 - Bench International
Creative Biolabs: Illuminate Neurological Disease Research and Therapy Development with Customized Animal Models
Creative Biolabs is proud to announce its new-year resolution to dive deeper into sourcing professional animal model solutions for neurological disorder studies. - March 15, 2024 - Creative Biolabs
Eminent Spine's 3D Titanium Anterior Lumbar Stand-Alone System Usage Report and Clinical Study
Eminent Spine's 3D Titanium ALIF Stand-Alone System received FDA 510(K) clearance in October 2022 and has reported 102 total implants and 273 screws used in operations. - March 14, 2024 - Eminent Spine
Innovation in Healthcare: Medical Websites Vie for Coveted Best Medical Website WebAward
The Web Marketing Association is looking for the best medical websites in the world as part of their 28th annual international WebAward Competition for Web site development at www.webaward.org. The WebAwards is the standards-defining competition that sets benchmarks for 90 industries, including healthcare, healthcare provider, medical, medical equipment, biotechnology and pharmaceutical websites. - March 13, 2024 - Web Marketing Association
DNA Data Storage Alliance Releases Its First Specifications for Storage of Digital Data in DNA
Specifications define recommended methods for storing basic vendor and CODEC information within a DNA data storage archive. - March 12, 2024 - DNA Data Storage Alliance
M4 Engineering Inc. Announces the Opening of Midwest Technical Center
M4 Engineering Inc., a leading Engineering firm in conceptual design, analysis, and prototype development is happy to announce that it has opened an office in Shakopee, MN. This office aims to leverage M4’s extensive experience in Aerospace and advanced materials and assist commercial companies, startups, and government agencies in driving innovation and pushing technology envelopes. - February 29, 2024 - M4 Engineering
ALS TDI Launches ALS Trial Navigator: A Revolutionary Platform to Simplify Access to Clinical Trials
The ALS Therapy Development Insitute (ALS TDI) has announced the beta launch of the ALS Trial Navigator. This innovative set of tools is designed to guide people with ALS and caregivers through the process of finding and understanding ALS clinical trials – with the ultimate goal of personalizing the search process and helping users make informed decisions about participation in trials. - February 29, 2024 - ALS Therapy Development Institute
Creative Biolabs Supplies Recombinant Antibodies for Pharmaceutical Breakthroughs
Creative Biolabs reaffirmed its dedication to supplying high-quality antibody reagents in 2024. - February 28, 2024 - Creative Biolabs
Gotham Biotech’s Histoplasma Urinary Antigen EIA Kit Now Available for Purchase as Histoplasma Spreads in the U.S.
Histoplasmosis is a systemic disease caused by the thermally dimorphic fungus Histoplasma capsulatum. H. capsulatum is distributed worldwide and endemic to the Ohio and Mississippi River Valleys, where the CDC estimates 60% to 90% of people who live in the region have been exposed to the fungus at some point during their life, and to certain regions of Central and South America. Medicare records from 2007 to 2016 have found cases of histoplasmosis have now spread to 47 states and Washington, DC. - February 15, 2024 - Gotham Biotech
Bench International and Deloitte Launch the "Bench and Deloitte Life Sciences Tech Innovation Award" to Celebrate Outstanding Women in Life Sciences
First-ever award to be presented on March 14, during LAMedTechWeek, at BioscienceLA. - February 13, 2024 - Bench International
Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report
Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC
WorldUpstart Launches Next U.S. Market Gateway Accelerator with 11 Impressive International MedTech and Life Science Companies
WorldUpstart launched the Winter 2024 U.S. Market Accelerator with eleven international Life Science and MedTech companies poised for growth. Given that only 20% of international companies typically succeed upon their initial entry into the U.S. market, the success rate of WorldUpstart’s accelerator program participants stands out at 40%. The program more than doubles the participant’s chances, creating a paradigm shift in their market entry strategy. - February 08, 2024 - WorldUpstart